# US 6,727,285 B1 · Use of D-arginine and/or L-arginine to protect the amino groups of biological substances from damage, inactivation, or modification by toxic carbonyls and/or dicarbonyls

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,285 B1
- Document ID: US6727285B1
- Status: Granted
- Kind: B1
- Application number: 09/079,329
- Filed: 1998-05-14
- Granted: 2004-04-27
- Earliest claimed: 1995-11-07
- Inventors: George M. Haik, Jr.
- Web page: https://patentgrep.com/patent/US6727285B1

## CPC

- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method of blocking dicarbonyls and carbonyls in vitro and in vivo includes using an effective quanity of an L- or D-arginine, substituted arginine, modified arginine or arginine-containing blocking agent. The method can, for example, include blocking toxic dicarbonyls and carbonyls in a patient suffering from a condition associated with toxic carbonyls and/or dicarbonyls, by administering to the patient a therapeutically effective dose of an L- or D-arginine, substituted arginine, modified arginine or arginine-containing blocking agent.

## Claims

### Claim 1

A method of blocking toxic carbonyl containing compounds and/or dicarbonyl containing compounds in a subject suffering from a condition associated with carbonyl containing compounds and/or dicarbonyl containing compounds by treating blood and/or blood products in a dialysis system for return to the subject comprising administering in the dialysis system a therapeutically effective dose of D-arginine to the subject's blood and/or blood products.

### Claim 2 (depends on 1)

The method of claim 1, wherein the D-arginine is administered to blood or blood products, as filterable wash or unremoved treatment, and at molar concentrations of arginine equal to 0.001 mg/100 ml to 60 mg/100 ml of arginine hydrochloride to blood or blood products.

### Claim 3 (depends on 1)

The method of claim 1, wherein the D-arginine is administered to blood or blood products, as filterable wash or unremoved treatment, and at molar concentrations of arginine equal to 0.005 mg/100 ml to 50 mg/100 ml of arginine hydrochloride to blood or blood products.

### Claim 4 (depends on 1)

The method of claim 1, wherein the D-arginine is administered to blood or blood products, as filterable wash or unremoved treatment, and at molar concentrations of arginine equal to 0.5 mg/100 ml to 40 mg/100 ml of arginine hydrochloride to blood or blood products.

### Claim 5

A method of treating a subject suffering from diabetes mellitus by treating blood and/or blood products in a dialysis system for return to the subject comprising administering in the dialysis system a therapeutically effective dose of D-arginine to the subject's blood and/or blood products.

### Claim 6 (depends on 5)

The method of claim 5, wherein the D-arginine is administered to blood or blood products, as filterable wash or unremoved treatment, and at molar concentrations of arginine equal to 0.001 mg/100 ml to 60 mg/100 ml of arginine hydrochloride to blood or blood products.

### Claim 7 (depends on 5)

The method of claim 5, wherein the D-arginine is administered to blood or blood products, as filterable wash or unremoved treatment, and at molar concentrations of arginine equal to 0.005 mg/100 ml to 50 mg/100 ml of arginine hydrochloride to blood or blood products.

### Claim 8 (depends on 5)

The method of claim 5, wherein the D-arginine is administered to blood or blood products, as filterable wash or unremoved treatment, and at molar concentrations of arginine equal to 0.5 mg/100 ml to 40 mg/100 ml of arginine hydrochloride to blood or blood products.
